Carisoprodol Property

Melting point:

92-92°C

Boiling point:

403.59°C (rough estimate)

Density 

1.1035 (rough estimate)

refractive index 

1.4560 (estimate)

storage temp. 

2-8°C

solubility 

Very slightly soluble in water, freely soluble in acetone, in alcohol and in methylene chloride.

form 

Solid

pka

pKa 4.2 (Uncertain)

color 

White to Off-White

Water Solubility 

<0.1 g/100 mL at 19.5 ºC

BCS Class

2/4

CAS DataBase Reference

78-44-4(CAS DataBase Reference)

NIST Chemistry Reference

Carisoprodol(78-44-4)

EPA Substance Registry System

Carisoprodol (78-44-4)

Safety

Hazard Codes 

Xn

Risk Statements 

22

Safety Statements 

36

RTECS 

FB3325000

HS Code 

29224999

Hazardous Substances Data

78-44-4(Hazardous Substances Data)

Toxicity

LD50 in mice, rats (mg/kg): 2340, 1320 orally; 980, 450 i.p. (Berger)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P501Dispose of contents/container to..…

Carisoprodol Chemical Properties,Usage,Production

Description

Carisoprodol (Item No. 30778) is an analytical reference standard categorized as a skeletal muscle relaxant. It also has sedative properties. Carisoprodol is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

Description

Carisoprodol (CRM) (Item No. ISO60206) is a certified reference material categorized as a skeletal muscle relaxant. It also has sedative properties. Carisoprodol is regulated as a Schedule IV compound in the United States. Carisoprodol (CRM) (Item No. ISO60206) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

Chemical Properties

White Solid

Originator

Soma,Wallace,US,1959

Uses

Carisoprodol suppresses interneuronal action of reticular formation of the spinal cord. It is used as an adjuvant drug for loss of flexibility of skeletal muscle as well as for relieving pain caused therein. Synonyms of this drug are rela, soma, carisoma, and sanoma.

Uses

Muscle relaxant (skeletal)
Carisoprodol has an onset of action of ca. 30min and a duration of 4–6h. It is administered orally. Presumably, it acts by inhibiting interneuronal activity in the spinal cord and the brainstem reticular formation. Clinically effective doses are accompanied by drowsiness or dizziness; its mechanism may involve sedation.Its CNS depressant effects are additive with those of ethanol and other psychotropic agents. Carisoprodol has a low potential for drug dependence.

Uses

For the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Definition

ChEBI: A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alter tion in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.

Preparation

Carisoprodol is Prepared by reaction of 2-methyl-2-propyl-1,3-pro-panediol with phosgene and ammonium hydroxide, then with isopropyl isocyanate.

Manufacturing Process

A cooled 10% solution of 1 mol of phosgene in toluene was added with stirring to a cooled solution of 1 mol of 2-methyl-2-propyl-1,3-propanediol and 2 mols of dimethylaniline also dissolved in toluene, at such a rate that the temperature of the mixture was maintained at about 25°C. The mixture was allowed to remain at this temperature for several hours, then cooled and extracted with cold 5% hydrochloric acid solution to remove the dimethylaniline. The toluene layer was dried using a suitable drying agent and the 2-methyl-2-propyl-3-hydroxypropyl chlorocarbonate used in subsequent reactions in the form of its solution in anhydrous toluene.
A quantity of solution obtained as described containing 0.1 mol of the chlorocarbonate was treated with 0.2 mol of anhydrous isopropylamine and allowed to react at ordinary room temperature. The solution was cooled, extracted with dilute hydrochloric acid and the organic layer concentrated by evaporation of the solvent. The crude monocarbamate was purified by distilling at 86° to 88°C at about 0.01 mm. It was a clear, viscous liquid.
21.7 g (0.1 mol) of N-isopropyl-2-methyl-2-propyl-3-hydroxypropylcarbamate and 7.5 g (0.11 mol) of anhydrous sodium cyanate are stirred in 200 ml anhydrous chloroform in a suitable vessel equipped with a gas inlet tube,stirrer and thermometer. While cooling the vessel, anhydrous hydrogen chloride is passed into the stirred mixture slowly for 5 hours maintaining the temperature between 0° and 5°C. Alternatively ethyl urethane in the presence of aluminum isopropylate as a catalyst may be used in place of the sodium cyanates and HCl. The mixture is then allowed to stand at room temperature overnight.
The solid material is separated by filtration and the chloroform solution concentrated to an oil under reduced pressure. The oil is dissolved in 50 ml of trichloroethylene, the solution treated with charcoal, filtered and the filtrate added to 125 ml of hexane. The crystalline material which forms on standing at refrigerator temperature is removed by filtration, washed with light petroleum ether and dried at about 50°C. Approximately 20 g of product are obtained. On recrystallizing from trichloroethylene-hexane, 17.8 g of purified compound are obtained, MP 89° to 91°C.

brand name

Rela (Schering); Soma (Medpointe).

Therapeutic Function

Muscle relaxant

General Description

Carisoprodol, N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate, 2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate(Soma), is the mono-N-isopropyl–substituted relative ofmeprobamate. The structure is given in the discussion ofmeprobamate. It is indicated in acute skeletomuscular conditionscharacterized by pain, stiffness, and spasm. As canbe expected, a major side effect of the drug is drowsiness.

Air & Water Reactions

Insoluble in water.

Reactivity Profile

Carisoprodol is a carbamate ester. Carbamates are chemically similar to, but more reactive than amides. Like amides they form polymers such as polyurethane resins. Carbamates are incompatible with strong acids and bases, and especially incompatible with strong reducing agents such as hydrides. Flammable gaseous hydrogen is produced by the combination of active metals or nitrides with carbamates. Strongly oxidizing acids, peroxides, and hydroperoxides are incompatible with carbamates.

Health Hazard

SYMPTOMS: The most common symptoms of exposure to Carisoprodol are drowsiness and hives. Other symptoms may include nausea, vomiting, epigastric distress, vertigo, ataxia, tremors, agitation, irritability, headache, insomnia, fainting, hiccups, visual disturbances, asthma, fever, hypotension, excitement and paralysis.

Fire Hazard

Flash point data for Carisoprodol are not available, but Carisoprodol it probably combustible.

Synthesis

Carisoprodol, N-iso-propyl-2-methyl-2-propyl-1,3-propanediol (15.3.12), is synthesized by reacting 2-methyl-2-propylpropanediol-1,3 dicarbamate with 1 mol of phosgene, forming the chloroformate (15.3.10), from which carbamate (15.3.11) is formed by reacting it with isopropylamine. Reacting this with either urethane or sodium cyanate gives carisoprodol (15.3.12).